ProPharma Group Announces New President / CEO

April 24, 2018

ProPharma Group announced today that Dawn Sherman has been named President and CEO, effective May 14, 2018.

A veteran in leading healthcare-focused businesses, Dawn brings extensive international strategy and operational experience to ProPharma Group. Her experience in setting strategy, leading businesses with large contact centers and her hands-on involvement leading consulting firms align with ProPharma Group’s goals to strengthen our global footprint while continuing both our organic growth and additional acquisitions.

“ProPharma Group is very fortunate to have Dawn join our organization at this time,” said Jeff Hargroves, Founder and current President and CEO. “We are confident that her experience will allow us to accelerate our financial and global growth as a leading provider of compliance related services to the pharmaceutical and medical device industries.”

Dawn has held multiple executive leadership positions over the years, most recently as President of EnvisionRxOptions, a RiteAid subsidiary. In this role she had responsibility for the pharmacy benefit management and technology company lines of business. Previously, she was Chief Operating Officer (COO) for Teva Pharmaceuticals Europe B.V., where her focus included strategy and innovation for patient solutions, commercial effectiveness, market access, business insights and market intelligence. “It is an honor to join ProPharma Group and the great people that have contributed to the Company’s success. I am incredibly excited about the many opportunities that lie ahead for this dynamic, growing business,” said Dawn Sherman.

Before joining Teva, Dawn was the Chief Operating Officer of Medco International, B.V. where she led activities related to integrating and operationalizing international business opportunities within Medco. “Dawn has been tremendously successful in building and leading international organizations, and we are excited to have her join the ProPharma Group team to lead the Company through its next phase of growth,” said Michael Farah, Partner at Linden Capital Partners.

Dawn succeeds Jeff Hargroves, Founder and CEO of ProPharma Group. Jeff will be stepping down to spend more time focusing on his family and philanthropic initiatives. Jeff will continue as an active member of the Board.


About ProPharma Group

ProPharma Group, a portfolio company of Linden Capital Partners, is a global industry leader in comprehensive compliance services that span the entire lifecycle of pharmaceuticals, biologics, and devices. ProPharma Group has more than 750 colleagues around the world providing medical information, pharmacovigilance as well as other compliance-related services.

About Linden Capital Partners

Linden Capital Partners is Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life sciences industries. Linden’s strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare.


May 12, 2015

ProPharma Group Acquires Minnesota-based PROSAR

Overland Park, Kansas, May 13, 2015 - ProPharma Group, a comprehensive compliance services company serving the pharmaceutical, biotechnology, and medical device industries, today announced its...

ProPharma Group Logo and Drug Safety Solutions acquisition announcement banner.

May 27, 2017

ProPharma Group Acquires Drug Safety Solutions

ProPharma Group announces the acquisition of Drug Safety Solutions, a clinical safety company based in Reunion, Florida. Drug Safety Solutions’ clinical safety team and operations will join ProPharma...

December 15, 2020

Mydecine Innovations Group Engages ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

DENVER, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research,...